Safety Study of Flavocoxid in Duchenne Muscular Dystrophy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Safety Study of Flavocoxid in Duchenne Muscular Dystrophy

key information

study id #: NCT01335295

condition: Duchenne Muscular Dystrophy

status: completed


Objective of this study is to evaluate safety and tolerability of flavocoxid administered at the daily oral dose of 500 or 1000 mg/die for one year in DMD patients, alone or in association with steroids (deflazacort on alternate days) started at least one year before. The investigators will also perform a multidimensional clinical evaluation covering functional and muscle strength and quality of life (QoL)assessments.

intervention: Flavocoxid

mechanism of action: Antioxidant to reduce inflammation


last updated: November 21, 2018

study details

start date: March 2011

estimated completion: December 2013

phase of development: Phase 1

size / enrollment: 20

primary outcomes:

  • All adverse events and laboratory or ECG abnormalities [ Time Frame: 1 year ]

secondary outcomes:

  • Motor assessments and biochemical evaluation [ Time Frame: 1 year ]
    Outcome measures will include:
    - Functional tests: 6- minute walk test, North Star Ambulatory Assessment (NSAA) with timed items
    - Medical Research Council (MRC) score of upper and lower limbs;
    - Maximum voluntary isometric contraction (MVIC)
    - Quality of Life (QoL) evaluation ;
    - Forced vital capacity (FVC) with spirometer . Changes in biomarkers

inclusion criteria:
• clinical diagnosis of DMD, confirmed by muscle biopsy and molecular analysis by MPLA;
• range of age between 4 -16 years;
• unaided ambulation for at least 75 meters, unassisted during the Screening 6MWT. Other personal assistance or use of assistive devices for ambulation (eg, short leg braces, long leg braces or walkers) is not permitted.
• follow-up of at least 1 year before baseline with the selected motor outcome measures;
• patients able to perform evaluation tests;
• patient legally authorized representative (LAR) able to understand and give the informed consent;
• absence of contra-indications to the use of flavocoxid (see below);
• written informed consent signed by LAR.

exclusion criteria:
• treatment with other drugs analogue, similar or interacting with flavocoxid or immunosuppressive therapy (other than corticosteroids) within 3 months prior to start of study treatment;
• exposure to another investigational drug or supplements within 2 months prior to start of study treatment;
• presence of cognitive impairment that could influence the performance of the evaluation tests;
• history of major surgical procedure within 30 days prior to start of study treatment;
• expectation of major surgical procedure (eg, scoliosis surgery) during the 12-month treatment period of the study;
• ongoing participation in any other therapeutic clinical study;
• expectation of recruitment in the forthcoming exon-51 trial;
• requirement for daytime ventilator assistance;
• presence of liver-diseases or assumption of any hepatotoxic agent;
• screening laboratory values out of the laboratory ranges if clinically meaningful;
• prior or ongoing medical condition (eg, concomitant illness, psychiatric condition, behavioral disorder, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.

study contacts

sponsor: University of Messina

investigators: Giuseppe Vita, MD

locations: Italy